Vicore starts collaboration with Alex Therapeutics to develop new digital therapeutic for patients with IPF

Vicore starts collaboration with Alex Therapeutics to develop new digital therapeutic for patients with IPF
- Webinar will be held today at 15:00 CET (9:00 am EST)
- Digital therapeutics expert Jessica Shull joins Vicore to drive DTx program
News provided by
Share this article
GOTHENBURG, Sweden, May 4, 2021 /PRNewswire/ -- 
Vicore Pharma Holding AB (publ) ("Vicore"), a rare disease pharmaceutical company developing innovative medicines for fibrotic lung disorders such as idiopathic pulmonary fibrosis (IPF), today announces the signing of an agreement with Alex Therapeutics AB for the development and clinical validation of a digital therapeutic (DTx) built on the "Alex DTx Platform". Vicore will hold a webinar at 15:00 CET (9 AM EST) today to outline the strategic importance and operational details of the new program.

Related Keywords

Sweden ,Stockholm ,Gothenburg ,Vastra Gotalands Lan ,Vicore Pharma ,John Drakenberg Renander ,Carl Johan Dalsgaard ,Vicore Pharma Holding ,Digital Therapeutics Alliance ,Alex Therapeutics ,Jessica Shull ,Digital Therapeutics ,Alex Therapeutic ,Johan Dalsgaard ,Drakenberg Renander ,Nasdaq Stockholm ,Nicotine Addiction ,Pharma Holding ,Vicore Pharma Holding Ab ,ஸ்வீடந் ,ஸ்டாக்‌ஹோல்ம் ,கோடெந்ப்ர்க் ,டிஜிட்டல் சிகிச்சை கூட்டணி ,ஜெசிகா ஷூல்ல் ,டிஜிட்டல் சிகிச்சை ,நாஸ்டாக் ஸ்டாக்‌ஹோல்ம் ,பார்மா வைத்திருத்தல் ,